1 Title: Antibiotic prescribing patterns by age and sex in England: why we need to take this 2 variation into account to evaluate antibiotic stewardship and AMR selection 3 Naomi R Waterlow^{1,2}, Tom Ashfield³, Gwenan M Knight^{1,2} 4 1 - Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease 5 Epidemiology, London School of Hygiene and Tropical Medicine, WC1E 7HT 6 2 - AMR Centre, London School of Hygiene and Tropical Medicine, WC1E 7HT 7 3 - The Signpost, Winchester, England 8 9 10 11

Structured Abstract

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

Conclusions

Objectives The drivers of antimicrobial resistance (AMR) likely vary substantially by different demographics. However, few complete open national detailed data exist on how antibiotic use (ABU) varies by both age and sex. Methods Here, prescriptions of antibiotics from General Practices in England for 2015-2023 disaggregated by 5-year age bands and sex were analysed at the national and Integrated Care Board (ICB) level. From a total of 249,578,795 prescriptions (across 9 years), 63% were given to women and the most prescribed were amoxicillin, nitrofurantoin and flucloxacillin sodium. Prescriptions per 100K population varied substantially across sex, age, geographical region, season, year, COVID-19 pandemic period and drug. Results Most antibiotics were prescribed more to women across most age bands (84% of antibiotics had more prescriptions to females across 50% of age bands). We show how this variation requires a more nuanced approach to comparing ABU across geographies and highlight that AWaRe targets are not met uniformly (young men have a higher proportion of "Watch" antibiotic prescriptions). We also show the impact on ABU of time-sensitive interruptions, including differential age-targeted influenza vaccination, COVID-19 restrictions and a shortage of amoxicillin combined with a Streptococcus A outbreak. Comparing to open access AMR data (MRSA in bloodstream infections) highlights the complexity of the link between ABU and AMR.

- 35 These detailed differences in ABU across England suggest that there should be large
- 36 variation in AMR burden by age and sex, which now need to be quantified with detailed
- 37 open access AMR data for a better intervention design.

Introduction

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

The global public health priority that is antimicrobial resistance (AMR) is driven by a population-specific combination of antibiotic selection and transmission. There are many global targets that focus on the reduction of antibacterial use (ABU). One such target already adopted by the WHO 13th General Programme of Work is to have at least 60% of total antibiotic consumption within the Access group of AWaRe antibiotics 1-3. More ambitiously, it has been proposed that 80% or more of oral antibiotic use could be Access ^{2,4}. To achieve such targets without affecting patient care, it will be key to produce nuanced information about ABU across different subpopulations. Most antibiotics are given outside of hospital settings 5,6 and previous studies have suggested that primary care antibiotic use (and hence exposure) varies substantially by age and by sex. A systematic review of primary care prescribing in 2016 suggested that women in high income settings receive a significantly higher number of prescriptions, particularly in the 16 to 54 years age band 7. This is supported by sub-national analyses⁸⁻¹⁰ from the UK, for example approximately twice as many antibiotic prescriptions given to women in 2013-2015, and 70% of all prescriptions after excluding antibiotics used to treat urinary tract infections (UTIs) 8. Antibiotic exposure rates are often "hockey-stick" shaped across age, with high levels in young children and an exponential increase with age 7,11. This is likely to reflect that different age/sex subgroups present with different rates of infections¹² and hence some level of appropriate prescription variation. For example women have higher rates of UTIs ¹³.

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

Antibiotic use also varies geographically at national and sub-national levels 14-16. Identifying outliers once patient composition is accounted for, is vital for improving antibiotic stewardship^{17,18}. To do this, various measures have been proposed such as the English STAR-PU ¹⁹ which uses different prescribing weights in different ages and sexes. Issues with this metric include the lack of accounting of co-morbidities 18 and the grouping of all antibiotics together masking variation in antibiotic use due to patient or GP-related factors ²⁰, although variation in prescribing may be decreasing over time ²¹. To reduce ABU many age-specific interventions could be considered, for example vaccination programmes are postulated to reduce both unnecessary and necessary antibiotic use ^{22,23}. Evidence that such a reduction in antibiotic exposure leads to reduced resistance is mixed²⁴, but age- and sex-disaggregated ABU could be used to reveal where there is a link between vaccination and ABU, as well as ABU and resistance rates. However, few ecological open access ABU or AMR data exist disaggregated by both age and sex. In one of the only detailed age and sex analyses, we have previously shown that AMR prevalence in bloodstream infections in Europe varies substantially by age, sex and bacteria-antibiotic combination ²⁵. Here we use 9 years of open access national data on antibiotic prescriptions from primary care in England available at an unprecedented level of both age and sex disaggregation to reveal the variation in ABU. We test assumptions about antibiotic weightings used for identifying prescribing outliers, conduct a nuanced analysis of AWaRe targets, generate estimates of the impact on ABU of age-based influenza vaccination, and explore the link between ABU and AMR. The patterns we find show the

- importance of such nuanced data and emphasise the need for more disaggregated AMR 83
- 84 data.

Materials & Methods

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

The number of primary care antibiotic prescriptions by 23 age bands and 3 genders in England & Wales was received through two freedom of information requests (FOI-01671, FOI-01975) ²⁶ to the NHS Business Service Authority (NHSBSA) Information Services Data Warehouse containing information from the NHSBSA Prescription Services. The first FOI contains data at General Practice (GP) and Integrated Care Board (ICB) level for England and some of Wales. The second is total national English data only. This data covers the 9 year period of April 2015 to December 2023 inclusive, by month, and includes all medicines from the British National Formulary (BNF) section 5.1: Antibacterial drugs ²⁷. Datapoints relating to fewer than 5 items prescribed were redacted by NHSBSA for privacy reasons. The 23 age bands were "0-1", "2-5" and then 5yr age bands up to "105+". The three gender classes included were "Male", "Female" and "Indeterminate" (where information does not confirm either Male or Female). We used number of items prescribed in our analysis, so as to avoid double-counting of patients ²⁶. Of total prescriptions in the dataset, 3.3% were prescribed to a patient of unknown gender or age band. We excluded these prescriptions from our analysis, although note that the frequency varied with time, with fewer unknowns over time (Appendix 1 section 2). We also excluded prescriptions given to individuals of "Indeterminate" gender, due to the small numbers (6247 Items, 0.0024%) and the antibiotics for which there were

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

less than an average of 10 prescriptions per year (22 antibiotics, Appendix 1 section 3). For our main analysis, we assumed all redacted numbers of items had a value 1 (from a possible 1,2,3 or 4), and run sensitivity analyses on this number (Appendix 1 Section 7). Population sizes by age were obtained from the Office for National Statistics (ONS) and mid-year estimates were used for each calendar year^{28,29} (Appendix 1 Section 4). We only included prescriptions for England in the analysis, and only those for 2023 were used for sub-national analyses, due to changes in the definitions of the ICBs. Data from NHSBSA provides "Gender", but most other sources use "Sex". We have assumed that we can match these two in this analysis. We calculated an updated STAR-PU weighting of antibiotic prescriptions per age band and sex, with smaller age bands ¹⁹. The updated comparison metric (UCM) weightings were calculated using females aged 66-70 as baseline (a subset of the STAR-PU 65-74 female baseline). Our UCM weightings were then applied to the ICBs in 2023, using the same STAR-PU principles: the new UCM weightings were multiplied by the relevant populations in each ICB, and the total prescriptions per UCM-population were used to compare ICBs. In addition, drug family-based weightings were calculated using the same methodology ("UCM-family"), but prescriptions from each drug family were used. For children aged up to 16 (the only age groups where there were sometimes no prescriptions) a value or 0.01 was used if there were no data in that age band, and limits were set of 0.01 to 100.

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

Drugs were classified into the AWaRe categories using a World Health Organisation reference table 30. Where drug names were not identical, these were manually matched (Appendix 1 section 1). Age bands covered by influenza vaccination were extracted from the annual UKHSA reports 31, and these were compared to prescriptions of antibiotics used in respiratory tract infections (RTIs)(defined as all drugs in the BNF categories "cephalosporins and other beta-lactams" and "penicillins"), excluding amoxicillin. Amoxicillin was excluded due to the very large number of prescriptions, and it's use in many varieties of infection ³². The influenza season was defined as 1st of October to 30th March inclusive. The number of prescriptions given to patients in age bands that matched closely to the vaccination groups was calculated where possible (0-1, 2-5, 5-10, 11-15, 50-65, 65+). We extracted the only publicly available data on AMR infection split by age and sex. This was for Staphylococcus aureus bloodstream infection data from UKHSA 33. The proportion of these BSIs due to S. aureus that were methicillin-resistant (MRSA) were compared to prescriptions of antibiotics in the BNF categories "cephalosporins and other beta-lactams" and "penicillins". Data collection and transmission rates were altered during the years of SARS-CoV-2 circulation and lockdowns, which we classified to be from March 2020 to June 2022 inclusive for England.

156

157

158

159

160

161

162

163

All code is available on github (https://github.com/NaomiWaterlow/prescription_foi) and was conducted in R 34. Sensitivity analysis The main issue to explore in the data was the uncertainty in the redacted small numbers ("*") when the number of prescriptions was between 1-4. In sensitivity analysis we explored changing our default value of 1 to 4 for (a) everyone, (b) males only and (c) children only (< 20yos).

Results

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

older ages (>55yos) in 2023.

Prescription data Over the 9-year period April 2015 to December 2023, 249,578,795 prescriptions of antibiotics were given in England. For the complete years (2016-2023), the average was 0.48 (range of 0.43, 0.52) prescriptions per person per year. The most frequently prescribed drugs were amoxicillin, nitrofurantoin and Flucloxacillin sodium(Table 1). 63% (63%, 64%) of drugs were prescribed to females, with 0.60 (0.54, 0.65) per person per year versus 0.36 (0.31, 0.40) in men. 13% (10%, 15%) of prescriptions were given to those <16yo, and 35% (33%, 37%) to those over 65yo. The highest overall prescription rate in both sexes was in the 86yo+ band (Appendix 1 section 5). COVID-19 mostly affected prescribing in those aged < 16yos (Appendix 1 section 5), mostly returning to pre-COVID-19 levels in the Spring of 2021. The top 20 prescribed antibiotics, totalling 98% of prescriptions, (Table 1) had annual prescription totals varying from 74,159 to over 6.5 million prescriptions, with most being prescribed more commonly to females (17/20) and most often in December (9/20) or January (5/20). Those prescribed more to men were ciprofloxacin, co-trimoxazole and rifamixin. Just over half of the top 20 prescribed antibiotics had fewer prescriptions in 2023 than 2016 (11/20), with 61% of antibiotic having at least a 10% reduction in prescriptions between 2019 and 2023, although some had sex-based time variation (e.g. ofloxacin, Fig 1B). Most of the top 20 antibiotics (15/20) had the highest rates in

		Mean	% to	Тор	Total in			Top age band (2023)	
Antibiotic	Total	(annual)	females	month	2016	2019	2023	Females	Males
Amoxicillin	53,415,335	6,676,917	58	12	8,130,012	6,673,263	7,311,226	0-1,2-5,86+	0-1,2-5,86+
Nitrofurantoin	27,953,870	3,494,234	83	10	2,358,297	3,740,424	3,808,622	76-80,81-85,86+	76-80,81-85,86+
Flucloxacillin sodium	26,940,364	3,367,546	55	7	3,488,057	3,270,904	3,384,802	76-80,81-85,86+	76-80,81-85,86+
Doxycycline hyclate	22,868,632	2,858,579	60	12	2,415,657	2,772,514	3,804,564	76-80,81-85,86+	76-80,81-85,86+
Penicillin V	15,557,160	1,944,645	59	12	1,892,172	1,841,679	2,447,555	2-5,6-10,16-20,	0-1,2-5,6-10
Trimethoprim	14,439,590	1,804,949	75	1	3,087,875	1,488,922	1,428,569	76-80,81-85,86+	76-80,81-85,86+
Clarithromycin	14,417,677	1,802,210	63	1	2,077,261	1,845,315	1,743,846	76-80,81-85,86+	76-80,81-85,86+
Co-amoxiclav	9,181,476	1,147,684	60	1	1,304,696	1,094,885	1,092,620	76-80,81-85,86+	76-80,81-85,86+
Lymecycline	7,938,074	992,259	58	3	1,054,631	1,032,182	861,423	11-15,16-20,21-25	11-15,16-20,21-25
Cefalexin	5,910,292	738,786	80	12	748,696	668,339	816,579	76-80,81-85,86+	76-80,81-85,86+
Azithromycin	5,877,890	734,736	57	12	612,414	748,885	805,700	71-75,76-80,81-85	76-80,81-85,86+
Metronidazole	4,156,192	519,524	78	3	599,382	520,332	474,629	21-25,26-30,31-35	76-80,81-85,86+
Ciprofloxacin	3,564,433	445,554	48	1	532,816	445,243	355,804	76-80,81-85,86+	76-80,81-85,86+
Erythromycin	3,397,046	424,631	66	1	709,522	394,861	286,163	76-80,81-85,86+	76-80,81-85,86+
Oxytetracycline	2,432,724	304,090	51	3	463,514	310,851	178,452	61-65,66-70,76-80	71-75,76-80,81-85
Piv. hydrochloride	1,790,378	223,797	79	10	108,361	223,030	301,447	76-80,81-85,86+	76-80,81-85,86+
Ery. ethylsuccinate	1,576,325	197,041	50	12	341,227	171,870	164,552	0-1,2-5,6-10	0-1,2-5,6-10
Co-trimoxazole	1,417,031	177,129	44	12	129,051	173,722	228,051	66-70,76-80,81-85	76-80,81-85,86+
Meth. Hippurate	1,060,060	132,508	80	12	40,789	82,081	319,013	76-80,81-85,86+	76-80,81-85,86+
Rifaximin	593,273	74,159	41	12	33,589	71,036	109,205	56-60,61-65,66-70	56-60,61-65,66-70

Table 1: Summary data on number of prescriptions for the 20 most prescribed antibiotics (see Appendix 1 section 6 for all antibiotics) across the complete years of the data (2016-

189 2023) unless otherwise indicated. Red shading indicates more prescriptions are to females and "Top" month is the month with the most prescriptions of this antibiotic (1 = January),

when summing across the whole dataset. "Top age band (2023)" is the age band in 2023 with the highest prescription rate per 100k. Light green shading indicates relatively more

191 prescriptions to younger individuals vs top age bands all being 55yo or more (Ery. is Erythromycin. Co-amoxiclav is amoxicillin and clavulanic acid, Co-trimoxazole is trimethoprim

192 and sulfamethoxazole. Piv. = Pivmecillinam. Meth. = Methenamine.)

194

195

196

197

198

199

200

201

202

203

204

205

206

207

Twenty-eight antibiotics (38%) show an annual seasonal pattern (Fig 1A, Appendix 2) in prescriptions (pre-COVID-19), defined as having at least two months where prescriptions were 20% higher than the average number of prescriptions, averaged over years. These seasonal antibiotics, all had a decrease in prescriptions during the COVID-19- period, followed by a spike in late 2022 (Appendix 2) correlating with a Streptococcus A outbreak and amoxicillin shortage³⁵. For most age bands higher levels of prescription in females compared to males (Fig 1C), were observed (84% / 54% / 24% of antibiotics had more prescriptions to females in at least 50% / 75% / 90% of age bands respectively). Notable exceptions with higher prescriptions to males are quinolones, isoniazid and minocycline hydrochloride. For some ages the sex that receives the most prescriptions changes with age (e.g. colistimethate sodium, azithromycin and rifampicin have higher prescriptions in males in children, higher prescription rates in females in adults (Fig 1C)).




Figure 1: Variation in antibiotic prescribing by age and sex with examples and overall comparison A/B). Example prescription rate per 100'000 population for clarithromycin and ofloxacin respectively. Colours indicate age bands, facets indicate sex. Grey shading indicates years of COVID-19 interventions. See Appendix 2 for all antibiotics. C) Relative prescription rate by sex for prescribed medicines in 2023. Colours represents the log of the ratio, with blue indicating higher prescriptions in women, and green indicating higher prescriptions in men. Drugs are ordered by BNF classification, where the acronyms are: Clindamycin and lincomycin = "C&L", Cephalosporins and other betalactams = "Ceph's", Antileprotic drugs = "Lep", Metronidazole, tinidazole and ornidazole = "MTO", Sulphonamides and trimethoprim= "S&T", Antituberculosis drugs = "TB", Urinary-tract infections = "UTIs".

Antibiotic usage metric

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

We created an updated comparison metric (UCM), with smaller age bands than STAR-PU (Figure 2B). This resulted in more extreme values across age bands, ranging from 0.19 to 2 in our UCM, compared to a range of 0.2 – 1.3 in the 2013 STAR-PU with particularly higher values in older males (Figure 2A vs B). Values by BNF drug value varied considerably by age and sex ("UCM-family", Appendix 1 section 7).

The new-UCM ranking of ICBs (first column Fig 2C, lines in Fig 2D), changed substantially when applying the UCM-family (Fig 2C, points in Figure 2D). For example, ICB QRL ranks as a high prescriber with the new-UCM (6th overall, Fig 2C, red in Fig2C&D) but a low prescriber of quinolones (38th overall, Appendix 1 section 9). The range in UCM-family ranking decreased with more prescriptions (Fig 2D).




Figure 2: A)2013 STAR-PU values using England data. B) Updated Comparison Metric (UCM) using 2023 English data and more disaggregated age bands. Blue = high value, green = low value, centred around the baseline: females, 66-70 (white). C) Ranking of UCMs across English ICBs, grouped by colour into quarters: rank 1-10 (1), 11-20 (2), 21-30 (3) and 30-42 (4). The "Overall" column shows the ranking of ICBs using our UCM, and the other columns by UCM-family. Acronyms: Clindamycin and lincomycin = "C&L", Cephalosporins and other beta-lactams = "Ceph's", Antileprotic drugs = "Lep", Metronidazole, tinidazole and ornidazole = "MTO", Sulphonamides and trimethoprim="S&T", Antituberculosis drugs = "TB", Urinary-tract infections = "UTIs". D) Normalised prescriptions per English ICB and antibiotic (facet) for overall UCM (lines, same on each facet) and UCM-families (dots). In C) and D) the same three ICBs are highlighted with colour (blue, yellow and pink). n indicates the total number of prescriptions across all ICBs.

Antibiotic consumption targets

225

226

227

228

229

230

232

233

234

235

236

237

238

239

240

241

242

The WHO 60% "Access" prescribing target has been reached in England: 84% of primary care prescriptions were "Access" in 2023. However, the more ambitious 80% level is not being met in males ages 11-20, largely driven by a spike in prescriptions for lymecycline (Figure 3B), commonly prescribed for Acne ³⁶. The main Reserve drug prescribed by GPs in 2023 was colisitimethate sodium, which must be given by injection or as a nebuliser as it is not given orally ³⁷, likely under the direction of tertiary care, particularly for Cystic Fibrosis patients ^{38,39}. The percentage of antibiotics that were "Access" varied across ICBs by between 5.3% (females, aged 6-10) to 13.4% (males, aged 16-20) (Appendix 1 Section 10).




Figure 3: A) Percentage of total prescriptions in each of the AWaRe categories (row), by age band, sex (column) and year (colour). Dashed horizontal lines represent targets of 60% and 80% in the Access category, and dotted vertical lines are included for comparison across graphs. Note the difference in y-axis ranges. B) Total prescriptions in 2023 by AWaRe categories (row), age band and sex (columns). Key contributing drugs are highlighted by colour and vertical dotted lines are included for comparison across graphs.

Influenza vaccination

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

261

262

263

264

265

266

267

268

269

271

272

273

274

275

276

Comparing the relative rate of prescriptions commonly given for (suspected) RTIs before and after influenza vaccination programmes (Figure 4A) shows no clear impact. For example, compared to ages 15-50, RTI relative prescription rates declined by just under 5% in age band 6-10 following introduction of vaccination in 7-8yos (Figure 4A&B). However, in this same period the prescriptions in age bands 0-1 decreased by over 10%. There was an increase in relative prescriptions in all ages except older adults when vaccination was introduced in 4-5yos & 8-9yos. Vaccination of 50-65yos would likely have the largest impact (more people), but is hard to interpret, as this occurred during the COVID-19 years. No decrease in prescriptions in this age band compared to the other age bands was identified (Fig 4A).




Figure 4: A) Age band specific prescription rates of RTI antibiotics (penicillins, cephalosporins and other betalactams) relative to the rate in age band 15-50. Amoxicillin was excluded (see methods). The influenza season was defined as 1st of October to 30th March inclusive. Vertical lines indicate the year the introduction of vaccination in the labelled age band, and the COVID-19 years are shaded grey. B) Proportional change in the number of RTI prescriptions (excluding amoxicillin) from the influenza season of the previous year, by age band. Vertical lines

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

indicate the introduction of vaccinations in the named age bands C) Prescription rate of beta-lactam antibiotics (top row) and proportion of BSI due to resistant S. aureus (over all S. aureus BSI) for similar age bands (columns) . Impact on antimicrobial resistance (AMR) There was a lack of a clear link between prescribing and resistance rates by age and sex for S. aureus (Figure 4C). All age bands except ages 0-1 see higher prescriptions of betalactam antibiotics (those to which MRSA are resistant) in females, yet the proportion of BSIs due to MRSA is higher in males 45yo and over, and varies over time in 1-44yo. As opposed to prescriptions, a higher proportion of BSIs were due to MRSA in females in age band <1 over time. Sensitivity analyses The majority of age bands across drugs show higher levels of prescription in females compared to males in all sensitivity analysis. When the hidden low prescription numbers (*s) were all set to the maximum possible value (4 instead of 1, equating to 0.13% instead of 0.033% of all prescriptions), 85% / 55% / 27% of antibiotics had more prescriptions to females in at least 50% / 75% / 90% of age bands respectively. The sensitivity analysis with the higher value (4) in males only or children only had highly similar levels of 78% / 55% /18% and 85% / 55% / 24% respectively (Appendix 1 section 7).

Discussion

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

We report here, for the first time, national data on all antibiotic prescriptions in primary care in England disaggregated by both 5yr age bands and sex. This unprecedented level of detail highlights huge variation and will be vital in bringing a more nuanced approach to AMR control. Whilst most antibiotics (15/20 of most prescribed antibiotics) had higher prescription rates in older ages (55yo+), a substantial proportion had higher prescription rates in children or younger adults. Matching previous reporting 7-10, women were prescribed more antibiotics, but this pattern was not uniform across age bands and the patterns seen would have been hidden if using only three age groupings. Higher prescribing in women is likely linked to both infection syndrome variation and to behavioural differences in consultation rates 8,40-43. We saw clear syndrome-linked prescribing: higher levels of UTI prescribing (nitrofurantoin and trimethoprim) in women and higher levels of prostate or gonorrhoea infection linked prescribing (ofloxacin) in men. Quantifying this age and sex variation provides a baseline for intervention targeting and may help assess prescription appropriateness. Most antibiotics (~60%) did not have a seasonal pattern of exposure. Those that did had a lower prescribing rate during COVID-19, likely reflecting that antibiotics prescribed seasonally are given for infections that are dependent on seasonal changes in transmission (schools / time indoors), or linked to other infections (e.g. respiratory

viruses ^{44,45}). Supporting this theory is the rapid increase in prescribing in late 2022

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

which coincided with a Streptococcus A outbreak and a wide increase in prevalence of respiratory virus infections linked to "re-opening" 46. How this could drive seasonality in AMR needs untangling. Other studies have found a similar decrease in prescribing during COVID-19 in primary care in sub-national data in the UK 47 48, mostly driven by prescribing in children. These data allow for more subtle analysis of prescribing outliers. We found that STAR-PU likely underestimates prescribing to older adults, especially males and that a metric split by antibiotic family would better identify outliers. This analysis strengthens the case for updated STAR-PUs 49. England is exceeding the WHO "60% Access" targets for antibiotic use, and likely has been since 2018, like other European settings⁵⁰. However, this data shows the utility of knowing the variation by detailed age bands and sex: males aged 11-20 had less than 60% Access in 2015, rising to 70% in 2023 due to an increase in prescribing of the watch antibiotic lymecycline, likely for acne³⁶. Whilst also spiking in females, due to the higher overall prescribing in women, their proportion Access remains above 70%. Interventions to reduce antibiotic prescribing, including the Quality Premium, appear to be working in general in England, with most antibiotics (61%) having at least a 10% reduction in prescriptions between 2019 and 2023 51,52. Disaggregating by age and sex reveals subgroups where changes in prescribing practice could be further targeted e.g. ofloxacin use has increased in men since 2016, potentially linked to rises in gonorrhoea ⁵³. Interestingly, a large reduction in prescriptions is not evidently driven by more ages

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

being eligible for influenza vaccination: despite roughly 50% vaccine coverage we saw little prescription reduction in that 'flu season in the age group vaccinated nor in linked age groups known to benefit from 'flu vaccination of children (e.g. 65+ age band) 54,55. These results are lower than those previously reported (e.g. 29% reduction in antibiotic prescribing in one systematic review ²²) potentially due to our grouping antibiotics together, using wider age bands (to match vaccine targets) and not considering influenzas complexity (e.g. strain variation). The impact of influenza vaccinations may also be higher in other non-UK settings. When considering AMR selection, we found no obvious link between the age and sex disaggregated exposures of beta-lactam antibiotics in primary care and higher MRSA prevalence in bloodstream infections (BSIs) in England. However, MRSA is often a hospital-associated pathogen ⁵⁶, and BSIs are usually treated in hospitals, hence a lack of a strong link might have been expected but not no link. More broadly, we clearly see that women receive more antibiotics in primary care, which is at odds with higher male resistance rates in our previous research in BSIs across Europe ²⁵ and available UK data³³. Such patterns point to unexplained complexity in the pathways to resistance acquisition and potential intervention targets such as increased age or even sex-based prescribing recommendations. Untangling the link from ABU to AMR will require further age and sex disaggregated data but also information on other covariables such as patient ethnicity, deprivation level and co-morbidities 18,57. Whilst the data used here is unparalleled in its detail and completeness, more patient data was available at later time points (a total of 3.3% of prescriptions were excluded),

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

leading us to focus on the more complete 2023 data and we had to use sensitivity analyses to explore the hidden low numbers of prescriptions. Our data improves upon previous studies which have banded either patient age (in 10+ age bands), not considered disaggregation by sex or only focused on a subset of patient diagnoses 7-9. Moreover, much work in the UK is not all national data, using either only a subset of GPs 8,9,57,58 which although designed to be representative, may miss subtle geographical variation or incomplete market coverage (e.g. IQVIA has 89% market coverage in the UK ⁵⁰). However, here we only had access to prescription data, with no measure of the propensity to take the prescribed medicine and whether this varies by age, sex, time or drug, no linked diagnosis or reason for prescribing, and only "Items", rather than a more specific quantification, such as daily defined doses (DDDs) or grams ⁵⁹. This is important as dose and duration of exposure is potentially relevant to the development of resistance 60-62. The generalisability of this analysis to other locations is likely low (except in related geographies e.g. Wales, Scotland etc.), as the results may not be applicable to countries with different prescribing guidelines and healthcare systems (e.g. US insurance-based prescribing 63, or over-the-counter availability in LMICs 64). However, many of the underlying infection syndromes and behaviour patterns may exist and hence our findings add to the increasing evidence that we need disaggregated data by age and sex to optimally intervene against AMR. Our analysis highlights the possibilities of using FOI requests in research. Future researchers could request additional UK data, e.g. at the GP level over larger time

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

periods to avoid the issue of small numbers, as well as exploring requests for further (ideally linked) data that could help answer questions on health inequality such as socio-economic status and secondary health care infrastructure 65. Overall, by showing wide antibiotic prescription variation across age and sex this research has demonstrated the need for a nuanced approach when exploring and understanding trends in ABU. Understanding how this affects the global public health problem that is AMR can only be done with matched age and sex disaggregated AMR data otherwise the impact of ABU targets, ageing populations and future interventions will be very hard to determine. **Acknowledgments** We would like to thank Yasmin Gant for supporting our understanding of reasons for antibiotic prescriptions, and Stephanie Evans for providing feedback on the manuscript. **Funding** GMK and NRW were supported by the Medical Research Council UK, https://www.ukri.org/opportunity/career-development-award/ (MR/W026643/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript **Transparency declarations** No conflicts to declare.

References

(2016).

438

417

418 1. WHO. Indicator Metadata Registry Details. https://www.who.int/data/gho/indicator-419 420 metadata-registry/imr-details/5767. 421 2. WHO. AWaRe. https://adoptaware.org/ (2021). 422 3. Sharland, M. et al. The WHO AWaRe Antibiotic Book: providing guidance on optimal 423 use and informing policy. Lancet Infect. Dis. 22, 1528–1530 (2022). 4. Mendelson, M. et al. Ensuring progress on sustainable access to effective 424 425 antibiotics at the 2024 UN General Assembly: a target-based approach. The Lancet 426 **403**, 2551–2564 (2024). 427 5. NHS England. Community pharmacy quality scheme 2020-22: findings and 428 recommendations from the antimicrobial stewardship initiatives. 429 https://www.england.nhs.uk/long-read/community-pharmacy-quality-scheme-2020-22-findings-and-recommendations-from-the-antimicrobial-stewardship-430 431 initiatives/ (2023). 432 6. Sijbom, M., Büchner, F. L., Saadah, N. H., Numans, M. E. & De Boer, M. G. J. Trends in 433 antibiotic selection pressure generated in primary care and their association with 434 sentinel antimicrobial resistance patterns in Europe. J. Antimicrob. Chemother. 78, 435 1245-1252 (2023). 7. Schröder, W. et al. Gender differences in antibiotic prescribing in the community: a 436 437 systematic review and meta-analysis. J. Antimicrob. Chemother. 71, 1800–1806

- 439 8. Smith, D. R. M., Dolk, F. C. K., Smieszek, T., Robotham, J. V. & Pouwels, K. B.
- 440 Understanding the gender gap in antibiotic prescribing: a cross-sectional analysis of
- 441 English primary care. BMJ Open 8, e020203 (2018).
- 9. Majeed, A. & Moser, K. Age- and sex-specific antibiotic prescribing patterns in 442
- 443 general practice in England and Wales in 1996. Br. J. Gen. Pract. 49, 735–736 (1999).
- 444 10. Hayward, G. N., Fisher, R. F. R., Spence, G. T. & Lasserson, D. S. Increase in
- antibiotic prescriptions in out-of-hours primary care in contrast to in-hours primary 445
- 446 care prescriptions: service evaluation in a population of 600000 patients. J.
- Antimicrob. Chemother. 71, 2612–2619 (2016). 447
- 11. Dolk, F. C. K., Pouwels, K. B., Smith, D. R. M., Robotham, J. V. & Smieszek, T. 448
- Antibiotics in primary care in England: which antibiotics are prescribed and for 449
- 450 which conditions? J. Antimicrob. Chemother. 73, ii2-ii10 (2018).
- 451 12. Dias, S. P., Brouwer, M. C. & van de Beek, D. Sex and Gender Differences in Bacterial
- Infections. Infect. Immun. 90, e0028322 (2022). 452
- 453 13. Foxman, B. The epidemiology of urinary tract infection. *Nat. Rev. Urol.* **7**, 653–660
- 454 (2010).
- 14. Mor, A. et al. Antibiotic use varies substantially among adults: a cross-national 455
- 456 study from five European Countries in the ARITMO project. *Infection* 43, 453–472
- 457 (2015).
- 458 15. European Centre for Disease Prevention and Control. Antimicrobial Consumption in
- 459 the EU/EEA (ESAC-Net) - Annual Epidemiological Report for 2021.
- https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-460
- consumption-europe-2021 (2022). 461

- 462 16. Browne, A. J. et al. Global antibiotic consumption and usage in humans, 2000–18: a
- 463 spatial modelling study. Lancet Planet. Health 5, e893–e904 (2021).
- 464 17. Motta, M., Wilcock, M. & Heald, A. Using defined daily doses to review antibiotic
- prescribing. *Prescriber* **32**, 19–25 (2021). 465
- 18. Hope, E. C. et al. Identifying English Practices that Are High Antibiotic Prescribers 466
- 467 Accounting for Comorbidities and Other Legitimate Medical Reasons for Variation.
- EClinicalMedicine 6, 36–41 (2018). 468
- 469 19. Lloyd, D. C., Harris, C. M. & Roberts, D. J. Specific therapeutic group age-sex related
- 470 prescribing units (STAR-PUs): weightings for analysing general practices' prescribing
- in England. BMJ 311, 991-994 (1995). 471
- 20. Krishnakumar, J. & Tsopra, R. What rationale do GPs use to choose a particular 472
- 473 antibiotic for a specific clinical situation? BMC Fam. Pract. 20, 178 (2019).
- 474 21. McDermott, D. Antimicrobial Prescribing Guidance - NICE & PHE Update. NECS
- Medicines Optimisation https://medicines.necsu.nhs.uk/antimicrobial-prescribing-475
- 476 guidance-nice-phe-update/ (2018).
- 477 22. van Heuvel, L., Paget, J., Dückers, M. & Caini, S. The impact of influenza and
- pneumococcal vaccination on antibiotic use: an updated systematic review and 478
- 479 meta-analysis. Antimicrob. Resist. Infect. Control 12, 70 (2023).
- 480 23. Barchitta, M., Maugeri, A., Vinci, R. & Agodi, A. The Inverse Relationship between
- 481 Influenza Vaccination and Antimicrobial Resistance: An Ecological Analysis of
- 482 Italian Data. Vaccines 10, 554 (2022).
- 24. Tadesse, B. T. et al. Vaccination to Reduce Antimicrobial Resistance Burden—Data 483
- Gaps and Future Research. Clin. Infect. Dis. 77, S597-S607 (2023). 484

485 25. Waterlow, N. R., Cooper, B. S., Robotham, J. V. & Knight, G. M. Antimicrobial 486 resistance prevalence in bloodstream infection in 29 European countries by age and 487 sex: An observational study. PLOS Med. 21, e1004301 (2024). 26. NHSBSA. FOI-01671 - Open Data Portal BETA. 488 489 https://opendata.nhsbsa.net/dataset/foi-01671 (2024). 490 27. Open Prescribing. BNF 5.1: Antibacterial drugs | OpenPrescribing. https://openprescribing.net/bnf/0501/ (2024). 491 28. ONS. Estimates of the population for the UK, England, Wales, Scotland, and 492 493 Northern Ireland - Office for National Statistics. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/ 494 populationestimates/datasets/populationestimatesforukenglandandwalesscotland 495 496 andnorthernireland (2024). 497 29. ONS. Health geographies population estimates (Accredited official statistics) -Office for National Statistics. 498 https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/ 499 500 populationestimates/datasets/clinicalcommissioninggroupmidyearpopulationesti 501 mates (2024). 502 30. WHO. AWaRe classification of antibiotics for evaluation and monitoring of use, 2023. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.04 503 504 (2023).505 31. Vaccine uptake guidance and the latest coverage data. GOV.UK 506 https://www.gov.uk/government/collections/vaccine-uptake (2024). 32. NICE. Amoxicillin | Drugs | BNF content published by NICE. 507

https://bnf.nice.org.uk/drugs/amoxicillin/ (2024).

508

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

33. MRSA, MSSA and Gram-negative bacteraemia and CDI: annual report. GOV.UK https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemiaand-c-difficile-infection-annual-epidemiological-commentary (2024). 34. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. (2018). 35. Gilchrist, K. Antibiotics prices surge in UK amid Strep A outbreak, leaving drugstores 'footing the bill'. CNBC https://www.cnbc.com/2022/12/13/strep-a-antibioticsprices-shortages-hit-drugstores-amid-uk-outbreak.html (2022). 36. Lymecycline | Drugs | BNF content published by NICE. https://bnf.nice.org.uk/drugs/lymecycline/ (2024). 37. Colistimethate sodium | Drugs | BNF content published by NICE. https://bnf.nice.org.uk/drugs/colistimethate-sodium/ (2024). 38. NHS. Inhaled Therapy for Adults and Children with Cystic Fibrosis. https://www.england.nhs.uk/wp-content/uploads/2018/07/Inhaled-therapy-foradults-and-children-with-cystic-fibrosis.pdf (2024). 39. NICE. Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis | Guidance | NICE. https://www.nice.org.uk/guidance/ta276/chapter/2-Clinical-need-and-practice (2013).40. Bagger, K., Nielsen, A. B. S., Siersma, V. & Bjerrum, L. Inappropriate antibiotic prescribing and demand for antibiotics in patients with upper respiratory tract infections is hardly different in female versus male patients as seen in primary care. Eur. J. Gen. Pract. 21, 118-123 (2015).

532 41. Briscoe, M. E. Why do people go to the doctor? Sex differences in the correlates of 533 GP consultation. Soc. Sci. Med. 1982 25, 507-513 (1987). 534 42. Wang, Y., Hunt, K., Nazareth, I., Freemantle, N. & Petersen, I. Do men consult less than women? An analysis of routinely collected UK general practice data. BMJ Open 535 536 **3**, e003320 (2013). 537 43. Harvey, E. J., De Brún, C., Casale, E., Finistrella, V. & Ashiru-Oredope, D. Influence of factors commonly known to be associated with health inequalities on antibiotic use 538 in high-income countries: a systematic scoping review. J. Antimicrob. Chemother. 539 **78**, 861–870 (2023). 540 44. Smith, A. M. & McCullers, J. A. Secondary Bacterial Infections in Influenza Virus 541 Infection Pathogenesis. Influenza Pathog. Control - Vol. I 385, 327-356 (2014). 542 543 45. Joseph, C., Togawa, Y. & Shindo, N. Bacterial and viral infections associated with 544 influenza. Influenza Other Respir. Viruses 7, 105–113 (2013). 46. Feinmann, J. Analysis reveals global post-covid surge in infectious diseases. BMJ 545 546 385, q1348 (2024). 547 47. Zhu, N. et al. Investigating the impact of COVID-19 on primary care antibiotic 548 prescribing in North West London across two epidemic waves. Clin. Microbiol. 549 Infect. 27, 762–768 (2021). 550 48. Rezel-Potts, E., L'Esperance, V. & Gulliford, M. C. Antimicrobial stewardship in the 551 UK during the COVID-19 pandemic: a population-based cohort study and 552 interrupted time-series analysis. Br. J. Gen. Pract. 71, e331–e338 (2021). 49. STAR-PUs - should we still be using them? | Bennett Institute for Applied Data 553 554 Science. https://www.bennett.ox.ac.uk/blog/2024/02/star-pus-should-we-still-be-

555

using-them/ (2024).

556 50. Simmons, B. et al. Progress towards antibiotic use targets in eight high-income 557 countries. Bull. World Health Organ. 99, 550-561 (2021). 558 51. Bou-Antoun, S. et al. Age-related decline in antibiotic prescribing for uncomplicated 559 respiratory tract infections in primary care in England following the introduction of a national financial incentive (the Quality Premium) for health commissioners to 560 reduce use of antibiotics in the community: an interrupted time series analysis. J. Antimicrob. Chemother. 73, (2018). 562 563 52. Balinskaite, V., Ap, J., A, H. & P, A. The Impact of a National Antimicrobial Stewardship Program on Antibiotic Prescribing in Primary Care: An Interrupted Time Series Analysis. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 69, (2019). 565 566 53. Sexually transmitted infections (STIs): annual data. GOV.UK 567 https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-568 annual-data-tables (2024). 54. Baguelin, M. et al. Assessing Optimal Target Populations for Influenza Vaccination 569 Programmes: An Evidence Synthesis and Modelling Study. PLoS Med. 10, (2013). 570 55. Schmidt-Ott, R. et al. Assessing direct and indirect effects of pediatric influenza vaccination in Germany by individual-based simulations. *Hum. Vaccines* 572 573 Immunother. 16, 836-845 (2019). 574 56. NHS England. Healthcare associated infections. 575 https://www.england.nhs.uk/patient-safety/healthcare-associated-infections/ 576 (2024).57. Shallcross, L., Beckley, N., Rait, G., Hayward, A. & Petersen, I. Antibiotic prescribing 577 frequency amongst patients in primary care: a cohort study using electronic health 578

records. J. Antimicrob. Chemother. 72, 1818–1824 (2017).

561

564

571

579

580 58. Palin, V. et al. Antibiotic prescribing for common infections in UK general practice: 581 variability and drivers. J. Antimicrob. Chemother. 74, 2440–2450 (2019). 582 59. Ways for prescribing to be measured. The Pharmaceutical Journal https://pharmaceutical-journal.com/article/ld/ways-for-prescribing-to-be-583 584 measured (2004). 585 60. Roberts, J. A., Kruger, P., Paterson, D. L. & Lipman, J. Antibiotic resistance--what's 586 dosing got to do with it? Crit. Care Med. 36, 2433–2440 (2008). 61. Teshome, B. F., Vouri, S. M., Hampton, N., Kollef, M. H. & Micek, S. T. Duration of 587 588 Exposure to Antipseudomonal β-Lactam Antibiotics in the Critically Ill and Development of New Resistance. Pharmacotherapy 39, 261–270 (2019). 589 590 62. Day, T. & Read, A. F. Does High-Dose Antimicrobial Chemotherapy Prevent the 591 Evolution of Resistance? PLoS Comput. Biol. 12, e1004689 (2016). 592 63. Olesen, S. W. et al. The distribution of antibiotic use and its association with antibiotic resistance. eLife 7, (2018). 593 64. Kanan, M. et al. Empowering Low- and Middle-Income Countries to Combat AMR by 594 595 Minimal Use of Antibiotics: A Way Forward. Antibiotics 12, 1504 (2023). 65. The Kings fund. Health inequalities in a nutshell. The King's Fund 596 597 https://www.kingsfund.org.uk/insight-and-analysis/data-and-charts/health-598 inequalities-nutshell (2024).

599